PPARG and Insulin resistance: In lipodystrophic peroxisome proliferator-activated receptor-γ (PPARγ) heterozygous mice with additional pharmacological inhibition of PPARγ/retinoid-X receptor (RXR) activity, adiponectin supplementation decreases insulin resistance by increasing fatty acid β-oxidation and reducing muscular and hepatic triglyceride accumulation (49); moreover, in a mouse model of HAART-associated lipodystrophy syndrome, adiponectin replacement therapy also markedly ameliorates ritonavir-induced increases of plasma triglyceride and free fatty acids levels (50).